Credit Suisse Group Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR)

Credit Suisse Group began coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a note issued to investors on Monday, TipRanks reports. The brokerage set a “buy” rating and a $83.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s price target suggests a potential upside of 74.22% from the company’s previous close.

A number of other brokerages have also issued reports on ESPR. ValuEngine upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, April 21st. Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Thursday, March 26th. BidaskClub lowered Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 5th. Bank of America began coverage on Esperion Therapeutics in a research report on Wednesday, April 1st. They set a “buy” rating and a $50.00 target price on the stock. Finally, Northland Securities began coverage on Esperion Therapeutics in a report on Tuesday, June 23rd. They issued a “hold” rating and a $42.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $78.50.

Shares of NASDAQ ESPR opened at $47.64 on Monday. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -4.95 and a beta of 2.16. Esperion Therapeutics has a 12 month low of $24.82 and a 12 month high of $76.98. The firm’s 50 day simple moving average is $44.53 and its 200-day simple moving average is $48.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.35 and a quick ratio of 2.33.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) EPS for the quarter, topping analysts’ consensus estimates of ($3.14) by $0.30. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $0.39 million. Esperion Therapeutics had a negative net margin of 5,492.02% and a negative return on equity of 627.38%. The business’s revenue was down 98.8% on a year-over-year basis. During the same quarter last year, the company earned $3.07 EPS. Analysts anticipate that Esperion Therapeutics will post -4.95 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace North America L.P. purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $1,416,000. Brinker Capital Inc. purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $462,000. Janus Henderson Group PLC purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $234,000. Mutual of America Capital Management LLC purchased a new position in shares of Esperion Therapeutics during the 1st quarter worth $1,016,000. Finally, Amalgamated Bank purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $277,000.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: Marijuana Stocks

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.